Dr Hachemi Kadri
Faculties, deparments and locations
- Faculty of Health, Science, Social Care and Education
- Department of Pharmacy
- School of Life Sciences, Pharmacy and Chemistry
- Penrhyn Road
Senior Lecturer in Pharmaceutical Chemistry
- Email:
- h.kadri@kingston.ac.uk
About
I joined Kingston University, London in January 2022 where I currently hold the position of Senior Lecturer in Pharmaceutical Chemistry. Prior to this, I was awarded the prestigious MRC GCRF Fellowship and was appointed as an Assistant Professor (Research) at the Chemistry Department, Durham University (January 2019-December 2021) where I also was a partner in the Global Network for the Neglected Tropical Diseases initiative. My MRC GCRF Fellowship research focused on developing innovative chemical approaches and tools to validate novel targets in Chagas disease and Leishmaniasis.
I completed my MPharm (Hons) degree at the University of Nottingham followed by a PhD in Medicinal Chemistry and Drug Design at the University of Cardiff, where I worked on the design, synthesis, and biological evaluation of novel anti-cancer agents. After my PhD, I worked on several drug discovery projects in key therapeutic areas including immuno-oncology, neurodegenerative and cardiovascular diseases at the University of Birmingham and later at Cardiff University
Qualifications
- Ph.D. in Medicinal Chemistry and Drug Design, Cardiff University
- MPharm (Hons) degree at the University of Nottingham
- GPhC registered pharmacist
Domains
Research in The Kadri Lab focuses on developing innovative chemical approaches for the discovery of novel therapeutics to address unmet global health needs particularly neglected tropical diseases (NTDs). Research is multidisciplinary spanning the fields of chemical biology, medicinal chemistry, computer-aided drug design, high throughput screening, protein crystallography, and biochemistry.
Funding:
- 2022-2023: RSC Research Fund grant
- 2019-2021: GCRF Fellowship award.
Specialisms
- Infectious diseases target validation and drug discovery
- Modulation of protein-protein interactions for therapeutic purposes
- Computer-aided drug design of novel therapeutic compounds
Publications
Nucleoside analogues for chagas disease and leishmaniasis therapy : current status and future perspectives
Nwoke, Emmanuel Awucha, Lowe, Silvester, Aldabbagh, Fawaz, Kalesh, Karunakaran and Kadri, Hachemi, 2024, Molecules (29), 22, pp 5234
Aryloxy diester phosphonamidate prodrugs of phosphoantigens (ProPAgens) as potent activators of Vγ9/Vδ2 T-cell immune responses
Kadri, Hachemi, Taher, Taher E., Xu, Qin, Sharif, Maria, Ashby, Elizabeth, Bryan, Richard T., Willcox, Benjamin E. and Mehellou, Youcef, 2020, Journal of Medicinal Chemistry (63), 19, pp 11258-11270
Aryloxy triester phosphoramidates as phosphoserine prodrugs : a proof of concept study
Miccoli, Ageo, Dhiani, Binar A., Thornton, Peter J., Lambourne, Olivia A., James, Edward, Kadri, Hachemi and Mehellou, Youcef, 2020, ChemMedChem (15), 8, pp 671-674
The photosensitising clinical agent verteporfin is an inhibitor of SPAK and OSR1 kinases
AlAmri, Mubarak A., Kadri, Hachemi, Alderwick, Luke J., Jeeves, Mark and Mehellou, Youcef, 2018, ChemBioChem (19), 19, pp 2072-2080
C-terminal phosphorylation of SPAK and OSR1 kinases promotes their binding and activation by the scaffolding protein MO25
Mehellou, Youcef, Alamri, Mubarak A., Dhiani, Binar A. and Kadri, Hachemi, 2018, Biochemical and Biophysical Research Communications (503), 3, pp 1868-1873
Niclosamide : a drug with many (re)purposes
Kadri, Hachemi, Lambourne, Olivia A. and Mehellou, Youcef, 2018, ChemMedChem (13), 11, pp 1088-1091
The anthelmintic drug niclosamide and its analogues activate the Parkinson's disease associated protein kinase PINK1
Barini, Erica, Miccoli, Ageo, Tinarelli, Federico, Mulholland, Katie, Kadri, Hachemi, Khanim, Farhat, Stojanovski, Laste, Read, Kevin D., Burness, Kerry, Blow, Julian J., Mehellou, Youcef and Muqit, Miratul M. K., 2018, ChemBioChem (19), 5, pp 425-429
BTN3A1 discriminates γδ T cell phosphoantigens from nonantigenic small molecules via a conformational sensor in its B30.2 domain
Salim, Mahboob, Knowles, Timothy J, Baker, Alfie T., Davey, Martin S., Jeeves, Mark, Sridhar, Pooja, Wilkie, John, Willcox, Carrie R., Kadri, Hachemi, Taher, Taher E., Vantourout, Pierre, Hayday, Adrian, Mehellou, Youcef, Mohammed, Fiyaz and Willcox, Benjamin E., 2017, ACS Chemical Biology (12), 10, pp 2631-2643
WNK signaling inhibitors as potential antihypertensive drugs
AlAmri, Mubarak A., Kadri, Hachemi, Dhiani, Binar A., Mahmood, Shumail, Elzwawi, Abdulrahman and Mehellou, Youcef, 2017, ChemMedChem (12), 20, pp 1677-1686
Rafoxanide and closantel inhibit SPAK and OSR1 kinases by binding to a highly conserved allosteric site on their C-terminal domains
AlAmri, Mubarak A., Kadri, Hachemi, Alderwick, Luke J., Simpkins, Nigel S. and Mehellou, Youcef, 2017, ChemMedChem (12), 9, pp 639-645
Kinetin riboside and its ProTides activate the Parkinson's disease associated PTEN-induced putative kinase 1 (PINK1) independent of mitochondrial depolarization
Osgerby, Laura, Lai, Yu-Chiang, Thornton, Peter J., Amalfitano, Joseph, Le Duff, Cécile S., Jabeen, Iqra, Kadri, Hachemi, Miccoli, Ageo, Tucker, James H. R., Muqit, Miratul M. K. and Mehellou, Youcef, 2017, Journal of Medicinal Chemistry (60), 8, pp 3518-3524
Towards the development of small-molecule MO25 binders as potential indirect SPAK/OSR1 kinase inhibitors
Kadri, Hachemi, Alamri, Mubarak A., Navratilova, Iva H., Alderwick, Luke J., Simpkins, Nigel S. and Mehellou, Youcef, 2017, ChemBioChem (18), 5, pp 460-465
Nucleoside phosphate and phosphonate prodrug clinical candidates
Thornton, Peter J., Kadri, Hachemi, Miccoli, Ageo and Mehellou, Youcef, 2016, Journal of Medicinal Chemistry (59), 23, pp 10400-10410
Synthesis and antioxidant properties of substituted 2-phenyl-1H-indoles
Karaaslan, Cigdem, Kadri, Hachemi, Coban, Tulay, Suzen, Sibel and Westwell, Andrew D., 2013, (23), 9, pp 2671-2674
The design, synthesis and antitumour evaluation of novel small molecule inhibitors of the Dishevelled PDZ domain
Kadri, H., Dale, T.C., Ewan, K.B.R. and Westwell, A.D., 2008, European Journal of Cancer Supplements (6), 12, pp 137
Synthesis and biological properties of benzothiazole, benzoxazole, and chromen-4-one analogues of the potent antitumor agent 2-(3,4-dimethoxyphenyl)-5-fluorobenzothiazole (PMX 610, NSC 721648)
Aiello, Stefania, Wells, Geoffrey, Stone, Erica L., Kadri, Hachemi, Bazzi, Rana, Bell, David R., Stevens, Malcolm F. G., Matthews, Charles S., Bradshaw, Tracey D. and Westwell, Andrew D., 2008, Journal of Medicinal Chemistry (51), 16, pp 5135-5139
The development of pro-apoptotic cancer therapeutics
Ziedan, Noha I., Kadri, Hachemi and Westwell, Andrew D., 2008, Mini-Reviews in Medicinal Chemistry (8), 7, pp 711-718
Synthesis and antitumour evaluation of novel 2- phenylbenzimidazoles
Kadri, Hachemi, Matthews, Charles S., Bradshaw, Tracey D., Stevens, Malcolm F. G. and Westwell, Andrew D., 2008, Journal of Enzyme Inhibition and Medicinal Chemistry (23), 5, pp 641-647
Impact of academic peer mentoring for pharmaceutical and chemical sciences foundation degree students at Kingston University
Mason, Thuy, Kadri, Hachemi, Mukhtar, Rahila and Khoder, Mouhamad(2024). In: Festival of Learning 2024, 20 Jun 2024 :Kingston upon Thames, U.K.